Why Kidney Cancer?
Melanoma and Kidney Cancer have long been considered sister diseases. Both have a dire prognosis and a very poor response to traditional chemotherapy and radiation therapy. Both are among the most responsive of all cancers to Immunotherapy. Statistics show 40% more patients die from Kidney Cancer each year than melanoma.
The most critical shortage of all funding areas for kidney Cancer has been in the small grant area. These small grant funds are largely supplied by non-profit organizations.
Small grants of $100,000 or less often leads to much larger governmental NCI grants.
Melanoma funding for the small grant area is about 20 times the current Kidney Cancer small grant funding. For Kidney Cancer research, the private funding for reviewed competitive grants appears to average around $500,000 per year from public records. By contrast, the two top funders of melanoma research provide over $10,000,000 in melanoma research grants each year.
This is a critical time for Kidney Cancer research funding. Right now due to the lack of funding, many Immunotherapy approaches are being explored in Melanoma, but aren’t being pursued in Kidney Cancer. Lack of funding is leading to a severe shortage of Kidney Cancer trials and resulting in more deaths.